Expression and Functional Significance of SOCS-1 and SOCS-3 in Astrocytes

Hongwei Qin, Sandrine A. Niyongere, Sun Jung Lee, Brandi J. Baker and Etty N. Benveniste

J Immunol 2008; 181:3167-3176; doi: 10.4049/jimmunol.181.5.3167
http://www.jimmunol.org/content/181/5/3167

References
This article cites 85 articles, 37 of which you can access for free at:
http://www.jimmunol.org/content/181/5/3167.full#ref-list-1

Subscription
Information about subscribing to J Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Expression and Functional Significance of SOCS-1 and SOCS-3 in Astrocytes

Hongwei Qin, Sandrine A. Niyongere, Sun Jung Lee, Brandi J. Baker, and Etty N. Benveniste

Astrocytes play a number of important physiological roles in CNS homeostasis. Inflammation stimulates astrocytes to secrete cytokines and chemokines that guide macrophages/microglia and T cells to sites of injury/inflammation. Herein, we describe how these processes are controlled by the suppressor of cytokine signaling (SOCS) proteins, a family of proteins that negatively regulate adaptive and innate immune responses. In this study, we describe that the immunomodulatory cytokine IFN-β induces SOCS-1 and SOCS-3 expression in primary astrocytes at the transcriptional level. SOCS-1 and SOCS-3 transcriptional activity is induced by IFN-β through IFN-γ activation site (GAS) elements within their promoters. Studies in STAT-1α-deficient astrocytes indicate that STAT-1α is required for IFN-β-induced SOCS-1 expression, while STAT-3 small interfering RNA studies demonstrate that IFN-β-induced SOCS-3 expression relies on STAT-3 activation. Specific small interfering RNA inhibition of IFN-β-inducible SOCS-1 and SOCS-3 in astrocytes enhances their proinflammatory responses to IFN-β stimulation, such as heightened expression of the chemokines CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), and CXCL10 (IP-10), and promoting chemotaxis of macrophages and CD4+ T cells. These results indicate that IFN-β induces SOCS-1 and SOCS-3 in primary astrocytes to attenuate its own chemokine-related inflammation in the CNS. The Journal of Immunology, 2008, 181: 3167–3176.

Astrocytes are the major glial cell type within the CNS and are critical for CNS homeostasis (1–3). Astrocytes regulate neuronal function by releasing neurotrophic factors, guiding neuronal development, and contributing to neurotransmitter metabolism (4, 5). Astrocytes also participate in synaptic plasticity and influence the formation of the blood-brain barrier (1, 4). Chemokines produced by astrocytes, such as MCP-1, MIP-1α, and IP-10, attract macrophages/microglia and T cells to CNS inflammatory sites (3, 4, 6, 7). Aberrant expression of chemokines accompanies CNS disorders such as multiple sclerosis (MS), Alzheimer’s disease, HIV-1-associated dementia, and brain injury/trauma (3). Astrocytes are involved in these disorders, but mechanisms by which astrocytes modulate inflammation within the CNS remain sketchy.

Type I IFNs elicit antiviral, antiproliferative, and immunomodulatory responses upon interaction with their receptors (8, 9). IFN-β primarily signals through the tyrosine kinases JAK1 and TYK2 to activate STAT-1α and STAT-2, which associate with IFN-regulatory factor-9 (IRF-9) to form the interferon-stimulated gene factor-3 (ISGF-3) complex. ISGF-3 up-regulates IFN-responsive genes by interacting with IFN-responsive sequence elements (ISRE) in their promoters (8). Less frequently, IFN-β induces STAT-1α to form homodimers that bind to IFN-γ activation site (GAS) elements (8). IFN-β also activates STAT-3, and the resulting STAT-1/STAT-3 heterodimers or STAT-3 homodimers bind to GAS elements to induce gene expression (10, 11). IFN-β-deficient mice develop a more severe form of experimental autoimmune encephalomyelitis (EAE) than do wild-type (WT) littermates, suggesting IFN-β may inhibit CNS inflammation (12, 13).

Inflammatory infiltrates in demyelinating lesions consist primarily of infiltrating macrophages and resident microglia, as well as infiltrating T cells (7). Chemokines, particularly IP-10, MCP-1, RANTES, and MIP-1α, play important roles in the initial recruitment of inflammatory cells to the CNS (7, 14–16). Studies in MCP-1-deficient mice indicate that MCP-1 has a nonredundant role in modulating monocyte and T cell infiltration during inflammation (17). MCP-1 has also been shown to attract neural progenitors to sites of neuroinflammation (18). IP-10 also participates in leukocyte recruitment to CNS inflammatory sites, and blocking IP-10 with neutralizing Abs markedly diminished the severity of EAE and reduced the levels of inflammatory T cells in the CNS (19). Astrocytes are also a source of RANTES, which functions as a chemoattractant and activator of T cells and monocytes, and induces cytokine and chemokine expression, suggesting that it can promote inflammatory cascades in the brain (20, 21).

Suppressors of cytokine signaling (SOCS) proteins (SOCS-1–7 and cytokine-inducible SH2-containing protein (CIS)) negatively regulate cytokine signaling pathways (22–24). The inducible SOCS-1 and SOCS-3 proteins inhibit the JAK-STAT pathway in a negative feedback loop, utilizing a variety of mechanisms (25). Targeted deletion of SOCS-3 in macrophages results in markedly enhanced IL-6-induced STAT-3 activation (26). Mice deficient in SOCS-3 in hematopoietic and endothelial cells demonstrate exacerbated IL-1-dependent arthritis (27), while forced expression of SOCS-3 in mouse arthritis models suppressed the induction and/or
development of disease (22, 28). Administration of a cell-penetrating SOCS-3 suppressed cytokine-mediated signal transduction associated with acute inflammation (29). Studies from the EAE animal model and MS patients suggest that lower levels of SOCS-3 are associated with relapsing EAE and MS (30, 31). Treatment with a mimetic of SOCS-1 (tyrosine kinase inhibitor peptide, or TKip) inhibited STAT-1 activation and had a protective effect on EAE disease, suggesting SOCS-1 exerts a beneficial effect in the EAE model (32). We previously demonstrated that IFN-β induces SOCS-1 expression in macrophages/microglia, which attenuates IFN-β-induced expression of the costimulatory protein CD40 (33). Similarly, LPS induces SOCS-3 expression in macrophages/microglia (34), and overexpression of SOCS-3 attenuates LPS-induced gene expression in these cells (35). These findings indicate that SOCS-1 and SOCS-3 inhibit inflammatory responses in macrophages/microglia.

Elucidating the function of SOCS-1 and SOCS-3 in astrocytes, and how they are expressed, is critical for understanding how astrocytes regulate inflammation in the CNS. Results from this study indicate that in primary murine astrocytes, IFN-β-mediated activation of STAT-1 and STAT-3 are responsible for SOCS-1 and SOCS-3 induction, respectively. Studies using astrocytes transfected with SOCS-1 or SOCS-3 small interfering RNA (siRNA) revealed that SOCS-1 and SOCS-3 inhibit IFN-β-induced expression of chemokines such as MCP-1, MIP-1β, RANTES, and IP-10, and inhibit chemotaxis of macrophages and T cells. These findings connect SOCS-1 and SOCS-3 induction in astrocytes with negative regulation of CNS inflammation.

Materials and Methods

Recombinant murine proteins and reagents

Recombinant murine IFN-β was from R&D Systems. Abs against phospho-STAT-1 Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Tyr705 were from Cell Signaling Technology. Abs against phospho-STAT-1 Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Tyr705 were from Cell Signaling Technology. Abs against STAT-1, STAT-2, and actin were from Santa Cruz Biotechnology. Abs against STAT-3, and actin were from Cell Signaling Technology. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690 and phospho-STAT-3 Tyr705 was from R&D Systems. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Tyr705 were from Cell Signaling Technology. Abs against STAT-1, STAT-2, and actin were from Santa Cruz Biotechnology. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690 and phospho-STAT-3 Tyr705 was from R&D Systems. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Tyr705 were from Cell Signaling Technology. Abs against STAT-1, STAT-2, and actin were from Santa Cruz Biotechnology. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690 and phospho-STAT-3 Tyr705 was from R&D Systems. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Tyr705 were from Cell Signaling Technology. Abs against STAT-1, STAT-2, and actin were from Santa Cruz Biotechnology. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690 and phospho-STAT-3 Tyr705 was from R&D Systems. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Tyr705 were from Cell Signaling Technology. Abs against STAT-1, STAT-2, and actin were from Santa Cruz Biotechnology. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690 and phospho-STAT-3 Tyr705 was from R&D Systems. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Tyr705 were from Cell Signaling Technology. Abs against STAT-1, STAT-2, and actin were from Santa Cruz Biotechnology. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690 and phospho-STAT-3 Tyr705 was from R&D Systems. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Tyr705 were from Cell Signaling Technology. Abs against STAT-1, STAT-2, and actin were from Santa Cruz Biotechnology. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690 and phospho-STAT-3 Tyr705 was from R&D Systems. Abs against phospho-STAT-1Tyr701, phospho-STAT-2 Tyr690, and phospho-STAT-3 Ty...
In accordance with the increases in mRNA levels, SOCS-1 and SOCS-3 proteins were detected after IFN-β/H9252 stimulation. SOCS-1 protein levels peaked at 4–8 h and were still elevated at 16 h (Fig. 1B), while SOCS-3 protein expression was detectable 30 min after IFN-β/H9252 stimulation, peaked at 4 h, and returned to basal levels at 24 h (Fig. 1B).

**FIGURE 1.** IFN-β induces SOCS-1 and SOCS-3 gene expression in primary astrocytes. The images shown are representative of at least three experiments. A, To measure IFN-β-induced increases in SOCS mRNA levels, primary astrocytes were treated with medium (UN) or IFN-β (100 U/ml) for up to 12 h, and total RNA was analyzed by RPA to measure SOCS-1, SOCS-3, and GAPDH mRNA levels. mRNA levels in the untreated sample were set at 1.0, and results are expressed as fold induction over these control levels. B, To determine the IFN-β-induced increases in SOCS protein levels, primary astrocytes were treated with IFN-β for up to 24 h and cell lysates immunoblotted with anti-SOCS-1 or anti-SOCS-3. The blots were stripped and reprobed with anti-actin as a loading control.

2 h (10.3-fold induction) and diminished at 4 h (Fig. 1A). In accordance with the increases in mRNA levels, SOCS-1 and SOCS-3 proteins were detected after IFN-β stimulation. SOCS-1 protein levels peaked at 4–8 h and were still elevated at 16 h (Fig. 1B), while SOCS-3 protein expression was detectable 30 min after IFN-β stimulation, peaked at 4 h, and returned to basal levels at 24 h (Fig. 1B).

**FIGURE 2.** IFN-β-induced activation of the murine SOCS-1 and SOCS-3 promoters requires GAS elements. Serial deletion and mutagenesis constructs of the SOCS-1 (A) and SOCS-3 (B) promoters are represented by line diagrams. Primary astrocytes were transiently transfected with 0.2 μg of the indicated SOCS-1 or SOCS-3 promoter constructs, allowed to recover for 4 h, treated with medium or IFN-β (100 U/ml) for 12 h, and analyzed for luciferase activity. Values were normalized to total protein levels, and the fold inductions shown are the IFN-β treatment values divided by untreated values. Data are the means ± SD of three experiments.

**IFN-β induction of SOCS-1 and SOCS-3 promoter activity requires functional GAS elements**

Since IFN-β induced SOCS-1 and SOCS-3 expression, we sought to define which cis-acting regulatory elements in their promoters were necessary for this induction. The SOCS-1 promoter (−1380 to +98 bp) contains multiple regulatory elements: three GAS elements (designated as GAS#1, GAS#2, and GAS#3), one GATA-1 site, one AP-1 site, two Sp1 sites, one AP-2 site, and one C/EBP element (Fig. 2A). We generated luciferase reporter-based constructs that sequentially deleted regulatory elements from the 5′ end of the SOCS-1 promoter. The reporter constructs were transiently transfected into primary astrocytes and treated with medium or IFN-β for 12 h. A luciferase construct containing the full-length SOCS-1 promoter served as a positive control. Our results indicate that IFN-β stimulated a 6.1-fold increase in WT SOCS-1 promoter activity. Deletion of the GATA-1, AP-1, Sp1, AP-2, GAS#1, and C/EBP elements (Δ1) did not significantly affect IFN-β-induced SOCS-1 promoter activity (Fig. 2A). Deletion of the GAS#2 site (Δ2) reduced IFN-β-induced SOCS-1 promoter activity by ~48% compared with Δ1 (Fig. 2A). In construct Δ3, deletion of both GAS#2 and GAS#3 abrogated IFN-β-induced SOCS-1 promoter activity (Fig. 2A). To further define the relative contributions of the GAS#2 and GAS#3 elements, assays were performed using constructs of the murine SOCS-1 promoter that specifically mutated these elements, but left the rest of the promoter intact (mGAS#2 and mGAS#3; Fig. 2A). Mutation of the GAS#2 element led to a ~53% inhibition of SOCS-1 promoter activity compared with the WT promoter, while mutation of the GAS#3 element inhibited IFN-β activation of the SOCS-1 promoter by ~67% (Fig. 2A). These results indicated that of all the potential cis-acting regulatory elements within the SOCS-1 promoter, these two GAS elements (GAS#2 and GAS#3) made the...
most important contributions to IFN-β-induced promoter activity in astrocytes.

The 1619-bp (−1492 to +127 bp) murine SOCS-3 promoter also contains many cis-regulatory targets: three AP-1 sites, one C/EBP site, one GATA-1 site, two Sp1 sites, one NF-κB site, and two GAS elements (GAS#1 and GAS#2). To ascertain the functional roles of these elements, we generated luciferase reporter-based deletion constructs from the 5′ end of the SOCS-3 promoter (35) (Fig. 2B). The WT SOCS-3 promoter or one of the deletion constructs was transiently transfected into astrocytes and treated with IFN-β for 12 h before assaying for luciferase activity. IFN-β stimulation mediated a 7.9-fold induction of WT SOCS-3 promoter activity. Deletion of the distal and medial AP-1 elements, the C/EBP element, the GATA-1 element, the NF-κB binding site, and the two Sp1 elements (Δ1) did not affect IFN-β-induced SOCS-3 promoter activity (Fig. 2B). Similarly, deletion of the proximal AP-1 element (Δ2) did not affect IFN-β-induced SOCS-3 promoter activity (Fig. 2B). In contrast, deletion of the distal GAS element (GAS#1; Δ3) reduced IFN-β-induced SOCS-3 promoter activity by 47% compared with Δ2. Deletion of both the GAS elements (GAS#1 and GAS#2; Δ4) abolished IFN-β-induced SOCS-3 promoter activity (Fig. 2B). Site-directed mutagenesis was used to individually mutate each GAS element in the murine SOCS-3 promoter (Fig. 2B). Mutation of the distal GAS#1 or the proximal GAS#2 element reduced IFN-β-induced SOCS-3 promoter activity by ~80% or 82%, respectively, compared with the Δ1 construct (Fig. 2B). These data indicated that among the proximal regulatory elements in the SOCS-3 promoter, the two GAS elements were most important for IFN-β-induced SOCS-3 promoter activity in astrocytes.

**STAT-1α is important for IFN-β-induced SOCS-1, but not SOCS-3, expression in primary astrocytes**

In T cells and macrophages, numerous stimuli, including IFN-γ, IFN-β, IL-6, IL-10, and growth hormone, are capable of inducing SOCS-1 and SOCS-3 expression by activating various STAT proteins (22, 28). To investigate the activation of STATs by IFN-β in primary astrocytes, the cells were treated in the absence or presence of IFN-β for up to 4 h, and then protein lysates were analyzed to detect the phosphorylation status of STAT-1α and STAT-3 (Fig. 3A). STAT-1α(Tyr701) was strongly phosphorylated after 0.25–2 h of IFN-β treatment, which diminished at 4 h. Similarly, phosphorylation of STAT-3(Tyr705) was detected at 0.25 h of IFN-β treatment, peaked between 0.5 and 1 h, and then diminished at 2–4 h. These results indicate that IFN-β activates the STAT-1/STAT-3 signaling pathways in primary astrocytes.

To determine whether STAT-1α was involved in IFN-β-induced SOCS-1 and SOCS-3 expression in astrocytes, we examined primary astrocytes from STAT-1α-deficient mice. After stimulation with IFN-β, these astrocytes did not express SOCS-1 mRNA, but SOCS-3 mRNA expression was much stronger than in WT astrocytes (Fig. 3B). These experiments demonstrated that IFN-β-mediated induction of SOCS-1 expression occurred in a STAT-1α-dependent manner, but IFN-β induction of SOCS-3 expression did not involve STAT-1α. In fact, the stronger SOCS-3 expression in STAT-1α-deficient astrocytes suggests that STAT-1α may negatively regulate SOCS-3 expression.

We next examined IFN-β activation of STAT-1α and STAT-3 in WT and STAT-1α-deficient primary astrocytes. In WT astrocytes, IFN-β induced strong and sustained STAT-1α tyrosine phosphorylation, while STAT-3 phosphorylation was much weaker (Fig. 3C). Note that the STAT-3 phosphorylation status in WT astrocytes from 129sv/SVEV mice is reduced (Fig. 3C) compared with that from astrocytes from C57BL/6J mice (Fig. 3A). IFN-β-induced STAT-3 phosphorylation was much stronger and prolonged in STAT-1α-deficient astrocytes than in WT cells (Fig. 3C). This further supports the idea that STAT-1α negatively regulates STAT-3, and suggests that enhanced STAT-3 signaling in the absence of STAT-1α may have contributed to SOCS-3 expression.

**STAT-3 is important for IFN-β-induced SOCS-3, but not SOCS-1, expression in primary astrocytes**

IFN-β induced the activation of both STAT-1 and STAT-3 in primary astrocytes, but the absence of STAT-1α enhanced STAT-3 activation and IFN-β-induced SOCS-3 mRNA (Fig. 3, B and C). Therefore, we investigated whether activation of STAT-3 was required for IFN-β to induce SOCS-3 gene expression. Using primary astrocytes from WT and STAT-1α-deficient mice, STAT-3 expression was inhibited by transfecting cells with a STAT-3-specific siRNA construct (or siRNA control) for 48 h. This inhibited
We next examined whether inhibition of STAT-3 affected IFN-β-induced SOCS-3 expression. Primary astrocytes from WT or STAT-1α-deficient mice were incubated with STAT-3-specific or control siRNA for 48 h, and then IFN-β was added for 1 or 2 h to induce SOCS-1 and SOCS-3 mRNA expression. IFN-β-induced SOCS-3 expression was higher in STAT-1α-deficient astrocytes than in WT cells (Fig. 4B, compare lanes 2–3 to lanes 8–9). In WT astrocytes, STAT-3 knockdown inhibited IFN-β-induced SOCS-3 expression by ~65% (Fig. 4B, compare lanes 2–3 to lanes 5–6), and the STAT-3 siRNA effect was more pronounced in STAT-1α−/− astrocytes (~82% inhibition of SOCS-3 expression; Fig. 4B, compare lanes 8–9 to lanes 11–12). IFN-β-induced SOCS-1 mRNA induction was abolished in STAT-1α-deficient cells (Fig. 4B), and STAT-3 siRNA did not significantly affect IFN-β-induced SOCS-1 mRNA expression in WT astrocytes (Fig. 4B, compare lanes 2–3 to lanes 5–6). These results collectively indicate that STAT-3 activation plays a critical role in IFN-β-induced SOCS-3 gene expression, but that it is dispensable for SOCS-1 expression.

STAT-2 is not critical for IFN-β induction of SOCS-1 and SOCS-3 expression

IFN-β primarily signals through the STAT-1/STAT-2/IRF-9 heterotrimer (8). Our data strongly implicated STAT-1 in IFN-β-mediated SOCS-1 expression, and since STAT-2 is also a component of the ISGF-3 complex, we sought to determine whether STAT-2 was involved in IFN-β-induced SOCS-1 gene expression. By transfecting primary astrocytes with siRNA against STAT-2, constitutive STAT-2 protein expression was suppressed by ~95% (Fig. 4C, compare lanes 1–3 to lanes 4–6) without affecting STAT-1 or STAT-3 expression. STAT-2 siRNA also inhibited IFN-β-induced STAT-2 phosphorylation by ~90% (Fig. 4C) without affecting IFN-β-induced STAT-1α and STAT-3 activation (Fig. 4C, compare lanes 2–3 to lanes 5–6). Upon evaluating SOCS-1 and SOCS-3 mRNA expression levels following IFN-β stimulation of STAT-2-depleted primary astrocytes, we found that SOCS-1 mRNA was slightly decreased (~30%) compared with siRNA control-treated cells, and expression of SOCS-3 mRNA was actually enhanced 1.9-fold by STAT-2 knockdown (Fig. 4D). These results indicate that IFN-β-induced SOCS-1 and SOCS-3 gene expression was moderately but not critically influenced by the STAT-2 transcription factor.

IFN-β induces expression of CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, and CXCL10/IP-10 in primary astrocytes

Chemokines are 8–14-kDa proteins responsible for the maturation and trafficking of leukocytes, particularly during inflammation (6, 7). We examined the effect of IFN-β on expression of several chemokines with essential roles in neuroinflammation. IFN-β induced expression of MCP-1, MIP-1α, MIP-1β, RANTES, and IP-10, although the kinetics differed among the chemokines (Fig. 5A). We observed MCP-1, MIP-1α, MIP-1β, and IP-10 mRNA after 1 h of IFN-β treatment; expression peaked between 2 and 4 h and decreased after 8 h (Fig. 5A). Although the astrocytes constitutively expressed RANTES, IFN-β enhanced RANTES mRNA expression after 2 h of treatment, and RANTES expression continued to increase over time (Fig. 5A). These data indicate that in primary astrocytes, IFN-β rapidly induces the expression of several chemokines that are relevant to the inflammatory process.

To determine whether STAT-1 is involved in IFN-β-induced chemokine expression, primary astrocytes from STAT-1α-deficient mice were examined. The absence of STAT-1α abrogated IFN-β induction of MCP-1, MIP-1α, MIP-1β, and RANTES.
mRNA expression (Fig. 5B). IFN-β induction of IP-10 was partially inhibited in STAT-1-deficient astrocytes compared with WT mice (Fig. 5B). These experiments demonstrate that IFN-β induction of chemokine expression occurred in a STAT-1α-dependent manner.

**SOCS-1 and SOCS-3 influence IFN-β-induced chemokine expression in primary astrocytes**

To determine whether SOCS-1 and/or SOCS-3 contribute to the regulation of these chemokines during IFN-β signaling, chemokine mRNA expression was evaluated in astrocytes transfected with SOCS-1 or SOCS-3 siRNA. Following a 48-h transfection, cells were treated in the absence or presence of IFN-β for up to 8 h and analyzed for SOCS-1, SOCS-3, and chemokine mRNA expression. Both targeting siRNA constructs effectively attenuated induction of the SOCS mRNAs by IFN-β. SOCS-1 siRNA inhibited induction of SOCS-1 by 57, 86, and 70% at 1, 2, and 4 h of IFN-β treatment, respectively (Fig. 6A, compare lanes 3–5 to lanes 9–11). SOCS-3 siRNA inhibited SOCS-3 induction by ~60% (1 h) and ~66% (2 h) (Fig. 6A, compare lanes 3–4 to lanes 15–16).

Compared with astrocytes expressing siRNA control, we observed enhanced IFN-β-induced SOCS-3 mRNA induction in the astrocytes transfected with SOCS-1 siRNA (Fig. 6A, compare lanes 3–5 to lanes 9–11) and stronger SOCS-1 mRNA expression in cells harboring SOCS-3 siRNA (Fig. 6A, compare lanes 3–5 to lanes 15–17). These results indicate that SOCS-1 negatively regulates the expression of SOCS-3, and vice versa.

We next examined the effect of SOCS-1 and SOCS-3 knockdown on induction of chemokine expression by IFN-β. Primary astrocytes transfected with SOCS-1 siRNA (Fig. 6B, middle panel)
exhibited more robust IFN-β-mediated chemokine induction (accompanying by slightly altered kinetics in some cases) than cells transfected with nontargeting siRNA (left panel). Throughout the IFN-β stimulation period, SOCS-1 inhibition enhanced CCL2/MCP-1, CCL4/MIP-1β, CCL5/RANTES, and CXCL10/IP-10 expression compared with siRNA control astrocytes. Additionally, SOCS-1 inhibition substantially enhanced the marginal CCL3/MIP-1α induction after a 1–2-h IFN-β treatment. For all chemokines, we observed similar but less pronounced results in astrocytes expressing SOCS-3 siRNA (Fig. 6B, right panel). Fig. 6C summarizes the effect of SOCS-1 or SOCS-3 knockout on chemokine mRNA expression. We chose one chemokine (IP-10) to analyze at the protein level. A significant enhancement of IFN-β-induced IP-10 expression was observed in SOCS-1 siRNA or SOCS-3 siRNA astrocytes compared with astrocytes with control siRNA (Fig. 6D). These results indicate that both SOCS-1 and SOCS-3 negatively regulate IFN-β-mediated induction of chemokines that are relevant to neuroinflammation.

**Knockdown of SOCS-1 and SOCS-3 enhances chemotaxis of macrophages and T cells to supernatants from IFN-β-treated astrocytes**

Astrocytic chemokine expression contributes to proinflammatory responses within the CNS by attracting resident microglia and infiltrating macrophages, as well as by promoting the infiltration of T cells into the CNS (7, 39–41). Our data demonstrate that SOCS-1 and SOCS-3 attenuate the induction of several chemokines in response to IFN-β. Therefore, we investigated whether this negative regulation was functionally significant; specifically, whether SOCS-1 or SOCS-3 levels negatively affected chemotraction of immune cells following IFN-β stimulation in primary astrocytes. In these experiments, we examined the ability of bone marrow-derived primary macrophages or spleen CD4+ T cells to migrate toward supernatants from IFN-β-stimulated astrocytes that were depleted in either SOCS-1 or SOCS-3. After transfecting primary astrocytes with SOCS-1 siRNA, SOCS-3 siRNA, or control siRNA for 48 h, cells were treated with medium or IFN-β for 16 and 24 h. Supernatants from the astrocytes were utilized in Transwell chemotaxis assays. Consistent with enhanced chemokine induction in the absence of SOCS proteins (Fig. 6), we observed significant enhancement of macrophage chemotaxis toward supernatants from SOCS-1 siRNA- or SOCS-3 siRNA-transfected astrocytes compared with control siRNA-transfected cells (Fig. 7A). The same effect was observed for CD4+ T cell chemotaxis (Fig. 7B). These results indicate that enhanced chemokine expression in SOCS-1- and SOCS-3-depleted astrocytes enhances their chemotactic properties for macrophages and CD4+ T cells.

**Discussion**

IFN-β is one of the most successful MS therapies because it decreases exacerbation rates and delays disease progression (42–44). Additionally, IFN-β treatment diminishes the clinical signs of EAE due to reduced cellular infiltration in the CNS (14, 45). IFN-β functions as an immunosuppressive agent by inhibiting class II MHC, MIF-9, and IL-12 expression, blocking Th1 development, inducing expression of the anti-inflammatory cytokines IL-10 and IL-4, inhibiting the inflammatory responses of macrophages/microglia, and improving blood-brain barrier integrity (9, 46, 47). However, IFN-β also induces expression of chemokines that modulate inflammatory and immune responses in the CNS (15, 21). These chemokines recruit leukocytes to inflammatory sites and may participate in regulating cytokine production by naive Th cells (48). Thus, IFN-β has both anti- and proinflammatory activities (9, 49).

In the present study, IFN-β induced the expression of SOCS-1 and SOCS-3 in astrocytes, and this induction was critical for controlling inflammatory responses in these cells. IFN-β utilizes distinct STAT proteins for induction of SOCS-1 and SOCS-3. The induction of SOCS-1 is dependent on STAT-1, while SOCS-3 induction relies on STAT-3 (Fig. 8). In support of STAT involvement, the results from analysis of the SOCS-1 and SOCS-3 promoters reveal that GAS elements are critical for IFN-β-induced SOCS-1 and SOCS-3 expression in astrocytes. We have recently shown that oncostatin M, an IL-6 family member, induces SOCS-3 expression in a manner dependent on STAT-3, ERK1/2, and JNK in astrocytes (50). In primary astrocytes, SOCS-1 and SOCS-3 expression is induced by IFN-γ (51) and also by peroxisome proliferator-activated receptor (PPAR)-γ agonists such as 15d-PGJ2 (15-deoxy-Δ12,14-prostaglandin J2) and rosiglitazone (52). PPAR-γ agonist induction of SOCS-1 and SOCS-3 occurs in a STAT-1-independent manner, with the possible involvement of protein kinase A and protein kinase C (52). Thus, STAT-dependent and -independent pathways lead to SOCS-1 and SOCS-3 expression in astrocytes in a stimulus-specific manner. Furthermore, there are CNS cell type-specific responses to IFN-β with respect to SOCS expression. Microglia are induced to express both SOCS-1 and SOCS-3 in response to IFN-β, similar to astrocytes, while in primary neurons, IFN-β induces SOCS-3, but not SOCS-1, expression (H. Qin and E. N. Benveniste, unpublished observation).

Studies in which the abundance of SOCS-1 and SOCS-3 has been enhanced or abrogated have established that these proteins are negative regulators of adaptive and innate immune responses
IFN-γ cytokines by inhibiting STAT-3 activation (61, 62). Targeted deletion of SOCS-3 deficiency is embryonically lethal (60). The major target of SOCS-3 has been used to elucidate the function of SOCS-3, given that silencing with siRNA significantly enhanced IFN-γ inhibition of signal transduction induced by LPS, IL-12, IL-4, and IL-6-induced STAT-3 activation (26). Additionally, SOCS-3 inhibition of the chemokines CCL2, CCL3, CCL4, and CCL5 upon IFN-γ treatment occurs in a STAT-1-dependent manner. IFN-γ-induced CXCL10 expression is partially dependent on STAT-1. SOCS-1 and SOCS-3 inhibit IFN-γ-induced chemokine expression in a negative feedback regulatory manner. See text for details.

In addition to inhibiting chemokine expression, SOCS proteins, particularly SOCS-3, inhibit chemokine-mediated chemotaxis in a variety of cell types, including T cells (75). This is due to the ability of SOCS-3 to bind to chemokine receptors, which then attenuates the chemotactic response. Thus, it will be of interest to determine whether the induction of SOCS-3 in glial cells (astrocytes, microglia) attenuates chemokine-mediated chemotaxis of these cells. Furthermore, this is an illustration of signaling cross-talk between cytokine and chemokine responses that affects a multitude of neuroinflammatory responses (7).

Polizzotto et al. (76) examined the temporal expression of SOCS-1 and SOCS-3 mRNA in the developing and adult nervous system, and they observed maximal expression from embryonic day 14 to postnatal day 8, which declined thereafter. During a variety of CNS disease states, both SOCS-1 and SOCS-3 are expressed. In the EAE model, SOCS-1 and SOCS-3 mRNA expression increased significantly in the cerebellum and spinal cord at the peak of disease activity and then declined (77). In a comparison of two models of EAE (SJL mice with relapsing-remitting EAE, and B6 mice with chronic EAE without complete remission), both SOCS-1 and SOCS-3 mRNA were elevated during active disease in both strains, although the B6 mice expressed less SOCS-3 (30). The failure of B6 mice to completely recover may be due to the lower levels of SOCS-3. Monocytes from relapsing-remitting (RR) MS patients constitutively express higher levels of activated STAT-3 than do cells from MS patients in remission. This was associated with decreased levels of SOCS-3 in RR MS patients compared with those in remission (31), suggesting an association of decreased SOCS-3 expression with MS relapses. In this regard, a recent study demonstrated that simvastatin increased SOCS-3 expression in monocytes from RR MS patients, which was associated with decreased STAT-3 phosphorylation, and inhibition of IL-6 and IL-23 expression (78). Thus, the induction of SOCS-3 expression by statins may be of therapeutic efficacy in MS.

SOCS-1 exerts a beneficial effect in the EAE model (32). Treatment with a mimetic of SOCS-1 (TKip) inhibited STAT-1 activation and had a protective effect on EAE disease. This was associated with lower myelin basic protein Ab titers, suppression of myelin basic protein-induced splenocyte proliferation, and reduction of TNF-α production. Therefore, SOCS-1 and SOCS-3 proteins are possible therapeutic targets for ameliorating pathological inflammation within the CNS.

Cell type-specific expression of SOCS-1 or SOCS-3 reveals complexity in SOCS function. Targeted expression of SOCS-1 in developing oligodendrocytes protects against the detrimental effects of IFN-γ (79). In a transgenic mouse line, proteolipid protein/SOCS-1, in which SOCS-1 is expressed in oligodendrocytes, EAE development occurs with an accelerated onset associated with early inflammation and increased oligodendrocyte apoptosis (80). In this model, IFN-γ exerts a protective effect on mature oligodendrocytes, which is abrogated upon SOCS-1 expression. Thus, SOCS-1 has differing effects on oligodendrocytes, dependent on their state of maturation. SOCS-1 inhibits inflammatory responses in macrophages/microglia (81, 82) and, as shown in this study, inhibits chemokine expression in astrocytes. SOCS-3 also has beneficial and detrimental functions in cells of the CNS. Conditional deletion of SOCS-3 in astrocytes, in the context of a spinal cord injury, enhanced migration of astrocytes and formation of glial scars (83). This resulted in less infiltration of inflammatory cells, sparing of myelin and oligodendrocytes, and improved functional recovery (83). These results imply that SOCS-3 represses the ability of reactive astrocytes to promote healing after spinal cord injury. Mice with conditional deletion of SOCS-3 in oligodendrocytes are protected against cuprizone-induced oligodendrocyte loss (84). SOCS-3 deletion allows LIF to inhibit myelin loss, and thus modulating SOCS-3 levels may serve as a therapeutic strategy for...
demyelinating diseases. However, in the context of stroke, SOCS-3 has a neuroprotective effect, as antisense knockdown of SOCS-3 increased the severity of stroke symptoms (85). Previous findings from our laboratory indicated that SOCS-3 attenuates inflammatory events in macrophages/microglia (35), and this study revealed that SOCS-3 in astrocytes exerts an inhibitory effect on chemokine expression. Because both SOCS-1 and SOCS-3 modify responses in microglia, astrocytes, and oligodendrocytes, understanding how SOCS expression is regulated in different CNS cell types will be clinically important. Studies to manipulate levels of SOCS expression in the CNS will aid in developing therapeutic strategies against neuroinflammatory diseases.

Acknowledgments

We thank Dr. Casey T. Weaver and James Oliver (University of Alabama at Birmingham, Birmingham, AL) for providing the STAT-1-deficient mice. We also thank Dr. Rebecca Goldstein for editorial assistance.

Disclosures

The authors have no financial conflicts of interest.

References


